Entellus Medical Inc. (NASDAQ:ENTL) Director Brian E. Farley sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 23rd. The shares were sold at an average price of $19.00, for a total value of $95,000.00. Following the completion of the transaction, the director now owns 494,581 shares in the company, valued at approximately $9,397,039. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Entellus Medical Inc. (NASDAQ:ENTL) opened at 18.43 on Thursday. The stock’s market capitalization is $347.66 million. Entellus Medical Inc. has a 12 month low of $13.72 and a 12 month high of $22.63. The company’s 50 day moving average price is $19.06 and its 200-day moving average price is $18.71.

Entellus Medical (NASDAQ:ENTL) last announced its quarterly earnings results on Thursday, November 3rd. The medical technology company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by $0.13. Entellus Medical had a negative net margin of 36.91% and a negative return on equity of 53.20%. The business had revenue of $17.90 million for the quarter, compared to analysts’ expectations of $17.93 million. During the same quarter in the prior year, the firm earned ($0.32) EPS. The firm’s revenue for the quarter was up 20.9% on a year-over-year basis. Equities analysts predict that Entellus Medical Inc. will post ($1.42) earnings per share for the current year.

Insider Buying and Selling by Quarter for Entellus Medical (NASDAQ:ENTL)

TRADEMARK VIOLATION NOTICE: This story was first reported by Daily Political and is the propert of of Daily Political. If you are viewing this story on another website, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be read at http://www.dailypolitical.com/2016/12/01/entellus-medical-inc-entl-director-sells-95000-00-in-stock.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in ENTL. Murphy Michael R increased its position in shares of Entellus Medical by 30.1% in the second quarter. Murphy Michael R now owns 627,441 shares of the medical technology company’s stock worth $11,463,000 after buying an additional 145,304 shares in the last quarter. Cortina Asset Management LLC increased its position in Entellus Medical by 39.2% in the second quarter. Cortina Asset Management LLC now owns 421,897 shares of the medical technology company’s stock worth $7,708,000 after buying an additional 118,745 shares during the period. Vanguard Group Inc. increased its position in Entellus Medical by 5.1% in the second quarter. Vanguard Group Inc. now owns 215,395 shares of the medical technology company’s stock worth $3,936,000 after buying an additional 10,532 shares during the period. BlackRock Fund Advisors increased its position in Entellus Medical by 4.3% in the third quarter. BlackRock Fund Advisors now owns 203,911 shares of the medical technology company’s stock worth $4,523,000 after buying an additional 8,393 shares during the period. Finally, Wasatch Advisors Inc. increased its position in Entellus Medical by 10.0% in the third quarter. Wasatch Advisors Inc. now owns 199,731 shares of the medical technology company’s stock worth $4,430,000 after buying an additional 18,150 shares during the period. Institutional investors own 71.55% of the company’s stock.

A number of research analysts have recently weighed in on the company. Deutsche Bank AG assumed coverage on Entellus Medical in a report on Thursday, October 6th. They issued a “buy” rating and a $26.00 target price on the stock. Zacks Investment Research lowered Entellus Medical from a “buy” rating to a “hold” rating in a report on Wednesday, October 5th. BTIG Research restated a “buy” rating and issued a $22.00 target price on shares of Entellus Medical in a report on Friday, August 5th. Finally, Canaccord Genuity restated a “buy” rating and issued a $23.00 target price on shares of Entellus Medical in a report on Friday, August 5th. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $22.75.

About Entellus Medical

Entellus Medical, Inc is a medical technology company. The Company is focused on the design, development and commercialization of products for the minimally invasive treatment of patients who are suffering from chronic sinusitis. The Company’s XprESS family of products is used by ear, nose and throat (ENT) physicians to treat patients with symptomatic inflammation of the nasal sinuses by opening narrowed or obstructed sinus drainage pathways using balloon sinus dilation.

5 Day Chart for NASDAQ:ENTL

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.